左卡巴斯汀联合表皮生长因子治疗儿童鼻中隔黏膜糜烂性鼻出血的临床疗效观察  

作　　者：邵琼[1] 钟水军[1] 臧军 

机构地区：[1]浙江省嘉兴市妇幼保健院,314000

出　　处：《浙江临床医学》2019年第12期1685-1686,共2页Zhejiang Clinical Medical Journal

摘　　要：目的 探讨左卡巴斯汀联合表皮生长因子治疗儿童鼻中隔黏膜糜烂性鼻出血的临床疗效.方法 将120例鼻中隔黏膜糜烂性鼻出血患儿随机分成对照组和观察组,每组各60例.对照组给予表皮生长因子治疗,观察组给予左卡巴斯汀联合表皮生长因子治疗,评估两组患儿间的鼻腔恢复通气时间、黏膜恢复时间、总有效率、复发率及不良反应.结果 观察组患儿的鼻腔恢复通气时间、黏膜修复时间显著短于对照组(P<0.05);观察组患儿的治疗总有效率显著高于对照组(P<0.05);观察组患儿8周的复发率显著低于对照组(P<0.05);两组间的不良反应发生率无显著差异(P>0.05).结论 左卡巴斯汀联合表皮生长因子治疗儿童鼻中隔黏膜糜烂性鼻出血的疗效确切,为临床应用提供了一定的参考价值.Objective To investigate the clinical efficacy of levocabastine combined with epidermal growth factor in the treatment of erosive epistaxis in children with nasal septum mucosa.Methods 120 patients with nasal septum erosive epistaxis were randomized into a control group and a treatment group.60 patients in each group were treated with epidermal growth factor(EGF)in the control group and levocabastine combined with epidermal growth factor(EGF)in the observation group.Two groups of children were evaluated with nasal ventilation time,mucosal recovery time,total effective rate,recurrence rate and adverse reactions.Results The nasal ventilation time and mucosal repair time in the observation group were significantly shorter than those in the control group(P<0.05);the total treatment efficiency in the observation group was significantly higher than that in the control group(P<0.05);the observation group was 8 weeks old in the observation group.The recurrence rate was significantly lower than that of the control group(P<0.05);there was no significant diflerenee in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of levocabastine combined with epidermal growth factor in the treatment of erosive epistaxis of nasal septum mucosa in children is definite,providing a certain reference value for clinical application.

关 键 词：左卡巴斯汀 表皮生长因子 鼻中隔黏膜糜烂 鼻出血 

分 类 号：R76[医药卫生—耳鼻咽喉科]